{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:58:53Z","timestamp":1790369933383,"version":"4.1.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Multiple myeloma (MM) exhibits marked clinical heterogeneity, with outcomes ranging from long-term disease control to rapid progression. Accurate identification of high-risk patients is therefore essential. Over the past decades, cytogenetic abnormalities have emerged as key prognostic factors, leading to successive staging systems integrating genomic data. However, limitations in existing models and a lack of standardization have hindered optimal risk assessment. The recent Consensus Genomic Staging (CGS) provides a unified definition of high-risk disease, emphasizing TP53 alterations, biallelic 1p32 deletion, and combinations of intermediate-risk lesions. Validation studies confirm its prognostic value, while also highlighting residual heterogeneity and the concept of functional high-risk disease. Advances in next-generation sequencing, particularly whole-genome sequencing, offer deeper insight into genomic complexity and may further refine stratification. Integration of genomic profiling, gene expression, and minimal residual disease assessment is likely to enhance precision medicine. Ultimately, improved risk stratification is critical to guide risk-adapted therapeutic strategies and improve outcomes in multiple myeloma.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000844","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:00:38Z","timestamp":1790366438000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Risk Stratification in Myeloma"],"prefix":"10.1097","volume":"32","author":[{"given":"Ana\u00efs","family":"Schavgoulidze","sequence":"first","affiliation":[{"name":"Myeloma Genomics Unit, University Institute of Cancer of Toulouse (IUCT)"},{"name":"University Hospital of Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Corre","sequence":"additional","affiliation":[{"name":"Myeloma Genomics Unit, University Institute of Cancer of Toulouse (IUCT)"},{"name":"University Hospital of Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9]]},"reference":[{"key":"R1-20260925","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1158\/2643-3230.BCD-21-0205","article-title":"Perspectives on the risk-stratified treatment of multiple myeloma","volume":"3","author":"Davies","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"R2-20260925","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.3324\/haematol.2019.236588","article-title":"Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk","volume":"105","author":"Corre","year":"2020","journal-title":"Haematologica"},{"key":"R3-20260925","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ajh.27327","article-title":"High-risk multiple myeloma: redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy","volume":"99","author":"Rees","year":"2024","journal-title":"Am J Hematol"},{"key":"R4-20260925","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1002\/ajh.70070","article-title":"European Myeloma Network consensus statement on functional high-risk multiple myeloma","volume":"100","author":"Lim","year":"2025","journal-title":"Am J Hematol"},{"key":"R5-20260925","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"R6-20260925","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International Myeloma Society\/International Myeloma Working Group Consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"key":"R7-20260925","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO.23.01277","article-title":"Genomic classification and individualized prognosis in multiple myeloma","volume":"42","author":"Maura","year":"2024","journal-title":"J Clin Oncol"},{"key":"R8-20260925","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"R9-20260925","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.3324\/haematol.2021.280566","article-title":"Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma","volume":"108","author":"Schavgoulidze","year":"2023","journal-title":"Haematologica"},{"key":"R10-20260925","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1182\/blood-2010-07-295105","article-title":"Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?","volume":"117","author":"Avet-Loiseau","year":"2011","journal-title":"Blood"},{"key":"R11-20260925","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41408-023-00933-4","article-title":"Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions","volume":"13","author":"Schavgoulidze","year":"2023","journal-title":"Blood Cancer J"},{"key":"R12-20260925","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.18.00776","article-title":"Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma","volume":"37","author":"Perrot","year":"2019","journal-title":"J Clin Oncol"},{"key":"R13-20260925","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","article-title":"A high-risk, double-hit, group of newly diagnosed myeloma identified by genomic analysis","volume":"33","author":"Walker","year":"2019","journal-title":"Leukemia"},{"key":"R14-20260925","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second Revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project","volume":"40","author":"D\u2019Agostino","year":"2022","journal-title":"J Clin Oncol"},{"key":"R15-20260925","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"key":"R16-20260925","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"R17-20260925","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jmoldx.2020.10.010","article-title":"Analytical validation of SKY92 for the identification of high-risk multiple myeloma","volume":"23","author":"van Beers","year":"2021","journal-title":"J Mol Diagn"},{"key":"R18-20260925","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1182\/blood.2019003098","article-title":"Del17p without TP53 mutation confers poor prognosis in intensively treated newly diagnosed multiple myeloma patients","volume":"135","author":"Corre","year":"2020","journal-title":"Blood"},{"key":"R19-20260925","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1182\/blood-2018-10-880831","article-title":"High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma","volume":"133","author":"Thakurta","year":"2019","journal-title":"Blood"},{"key":"R20-20260925","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.2022017863","article-title":"Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor","volume":"141","author":"Schavgoulidze","year":"2023","journal-title":"Blood"},{"key":"R21-20260925","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood.2025029999","article-title":"High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing","volume":"147","author":"Schavgoulidze","year":"2026","journal-title":"Blood"},{"key":"R22-20260925","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1200\/JCO-24-01253","article-title":"Co-occurrence of cytogenetic abnormalities and high-risk disease in newly diagnosed and relapsed\/refractory multiple myeloma","volume":"43","author":"Kaiser","year":"2025","journal-title":"J Clin Oncol"},{"key":"R23-20260925","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"R24-20260925","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R25-20260925","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"key":"R26-20260925","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat Commun"},{"key":"R27-20260925","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2017.345","article-title":"Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines","volume":"32","author":"Maura","year":"2018","journal-title":"Leukemia"},{"key":"R28-20260925","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41408-022-00673-x","article-title":"Structural variants shape the genomic landscape and clinical outcome of multiple myeloma","volume":"12","author":"Ashby","year":"2022","journal-title":"Blood Cancer J"},{"key":"R29-20260925","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood.2022016212","article-title":"The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM","volume":"141","author":"Stong","year":"2023","journal-title":"Blood"},{"issue":"(3)","key":"R30-20260925","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/blood.2025029999","article-title":"High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing","volume":"147","author":"Schavgoulidze","year":"2026","journal-title":"Blood"},{"key":"R31-20260925","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.2025029987","article-title":"Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling","volume":"146","author":"Beer","year":"2025","journal-title":"Blood"},{"key":"R32-20260925","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"key":"R33-20260925","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41467-018-04001-5","article-title":"Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma","volume":"9","author":"Manier","year":"2018","journal-title":"Nat Commun"},{"key":"R34-20260925","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1182\/blood.2023022540","article-title":"ctDNA improves prognostic prediction for patients with relapsed\/refractory MM receiving ixazomib, lenalidomide, and dexamethasone","volume":"143","author":"Kogure","year":"2024","journal-title":"Blood"},{"key":"R35-20260925","doi-asserted-by":"crossref","first-page":"363ra147","DOI":"10.1126\/scitranslmed.aac7037","article-title":"Genetic interrogation of circulating multiple myeloma cells at single-cell resolution","volume":"8","author":"Lohr","year":"2016","journal-title":"Sci Transl Med"},{"key":"R36-20260925","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.22.02567","article-title":"Daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra-high-risk multiple myeloma","volume":"41","author":"Kaiser","year":"2023","journal-title":"J Clin Oncol"},{"key":"R37-20260925","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1182\/blood.2023023597","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma","volume":"143","author":"Touzeau","year":"2024","journal-title":"Blood"},{"issue":"1","key":"R38-20260925","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1200\/JCO.23.01696","article-title":"Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.","volume":"42","author":"Leypoldt","year":"2024","journal-title":"J Clin Oncol"},{"key":"R39-20260925","doi-asserted-by":"crossref","first-page":"e433520","DOI":"10.1200\/EDBK_433520","article-title":"Navigating high-risk and ultrahigh-risk multiple myeloma: challenges and emerging strategies","volume":"44","author":"Rees","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R40-20260925","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"key":"R41-20260925","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood.2024027620","article-title":"Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results","volume":"146","author":"Corre","year":"2025","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:00:43Z","timestamp":1790366443000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PPO.0000000000000844"}},"subtitle":["Defining Precision in the Genomic Era"],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000844","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-04-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}